NCT06984328
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06984328
Title Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Genmab
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Tennessee Oncology, PLLC Nashville Tennessee 37203 United States Details
Pan American Center for Oncology Trials, LLC San Juan 00909 Puerto Rico Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field